FDA approves Wegovy to lower heart attack and stroke risk in overweight adults
OAN’s Abril Elfi
9:27 AM – Saturday, March 9, 2024
The FDA Approves Wegovy to Reduce Heart Attack and Stroke Risk
The Food and Drug Administration (FDA) has given its approval to the weight-loss drug Wegovy, allowing it to be prescribed as a means to reduce the risk of heart attack and stroke.
Novo Nordisk, the manufacturer of Wegovy, announced on Friday that the FDA has updated the drug’s label to include its potential in reducing heart issues among overweight adults.
Heart attack is currently the leading cause of death in the United States, according to the Centers for Disease Control and Prevention (CDC).
This label change was prompted by Novo Nordisk’s findings from a late-stage clinical trial involving over 17,000 adults with a history of heart disease who were either obese or overweight. The trial revealed that Wegovy reduced the risk of cardiovascular events, such as heart attacks and strokes, by 20% compared to a placebo.
As a result of this modification, more insurers and employers may now cover the medication.
It is important to note that Medicare is not permitted to pay for Wegovy or similar weight-loss drugs like Eli Lilly’s Zepbound, so insurance coverage for these medications is typically limited.
Novo Nordisk claims that Wegovy is the first medication authorized in the United States for both weight management and heart disease risk reduction.
Wegovy contains semaglutide, the active component found in the well-known diabetes medication Ozempic, which is often used off-label for weight loss.
Stay informed! Subscribe here to receive breaking news blasts directly to your inbox for free: https://www.oann.com/alerts
President Biden mourns the loss of Lincoln Riley at SOTU, Lara Trump becomes Co-Chair of the RNC and Sweet Baby Inc. is exposed.
Joe Biden’s speech writers may have their work cut out for them for the State of the Union. One America’s Nathaniel Mannor has more.
One Christian author explains how trangenderism is hurting America’s youth, and how Christians can fight back.
Arizona is facing a host of problems created by Democrat policies, especially those created by illegal immigration at its southern border.
UnitedHealth Group is likely to need several months to make a full recovery from one of the most disruptive hacks against America’s healthcare infrastructure.
Google has been touting the myriad innovations in the first building wholly designed and built by the web giant.
Investors have piled into Nvidia-focused ETFs this year on the frenzy around AI.
LinkedIn for the first time disclosed sales for its premium subscription business as the company sees an uptick in adoption of new AI tools.
rnrn
What are the potential implications of FDA approval and label update for insurance coverage of Wegovy?
Great interest to the medical community. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by increasing insulin secretion and decreasing glucagon secretion. It has been shown to promote weight loss by reducing appetite, increasing satiety, and improving insulin sensitivity.
The approval of Wegovy by the FDA is a significant milestone in the fight against obesity-related health issues. Obesity is a major risk factor for cardiovascular disease, including heart attacks and strokes. By offering a weight-loss drug that not only helps individuals shed excess pounds but also reduces their risk of heart attack and stroke, healthcare providers have a valuable tool to combat these life-threatening conditions.
The clinical trial conducted by Novo Nordisk demonstrated the efficacy and safety of Wegovy in reducing the incidence of cardiovascular events. With a 20% reduction in risk compared to a placebo, the drug has proven to be a game-changer in the management of both obesity and heart disease.
In addition to its benefits for patients, the FDA approval of Wegovy may have significant implications in terms of insurance coverage. With the updated label indicating its potential to reduce heart issues, more insurers and employers may now consider covering the medication. This is particularly important given the high healthcare costs associated with cardiovascular disease.
However, it should be noted that Medicare, the federal health insurance program for Americans aged 65 and older, is not permitted to cover Wegovy or other similar weight-loss drugs. Insurance coverage for these medications may still be limited, but the FDA approval and label update open the door for more individuals to have access to this potentially life-saving treatment.
Novo Nordisk’s achievement with Wegovy is also significant from a pharmaceutical standpoint. It is the first medication in the United States that is authorized for both weight management and heart disease risk reduction. This highlights the growing recognition of the complex relationship between obesity and cardiovascular health and underscores the importance of a comprehensive approach to tackling these interconnected issues.
As we continue to learn more about the potential benefits of Wegovy, it is crucial for healthcare providers to closely monitor patients using the drug. Like any medication, it may have side effects and should be prescribed and monitored by qualified healthcare professionals.
The FDA approval of Wegovy marks a major breakthrough in the treatment of obesity-related heart issues. By combining weight management and cardiovascular risk reduction into one medication, Novo Nordisk has opened up new possibilities for patients struggling with both conditions. As more research and clinical trials are conducted, we can expect further advancements in the field of obesity treatment and prevention, bringing us closer to a healthier future for all.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
*As an Amazon Associate I earn from qualifying purchases
Now loading...